Omega Therapeutics (OMGA) Q2 2024 earnings summary

Executive summary

• Omega Therapeutics is a clinical-stage biotech focused on programmable epigenomic mRNA medicines, with a lead program in hepatocellular carcinoma (HCC) and a pipeline spanning oncology and other diseases.

• Advanced MYCHELANGELO I trial for OTX-2002 in HCC, with dose expansion and new cohorts planned for Q4 2024.

• Demonstrated durable and precise gene upregulation with OMEGA platform at scientific meetings.

• Strengthened leadership with new Chief Business Officer and Board member appointments.

• The company reported a net loss of $16.3 million for Q2 2024 and $36.4 million for the first half of 2024, reflecting ongoing R&D investment and no product sales.

Financial highlights

• Cash and cash equivalents were $45.9 million as of June 30, 2024, expected to fund operations into Q1 2025.

• Q2 2024 collaboration revenue was $2.1 million, up 181% year-over-year, driven by the Novo Nordisk agreement.

• Research and development expenses decreased 48% year-over-year to $12.9 million in Q2 2024 due to lower external research, manufacturing, and personnel costs.

• General and administrative expenses fell 12% year-over-year to $5.8 million in Q2 2024, mainly from reduced personnel and consulting costs.

• Net loss per share was $0.30 for Q2 2024, compared to $0.54 in Q2 2023.

Outlook and guidance

• Cash runway is projected into the first quarter of 2025, with additional funding required to support future preclinical and clinical activities.

• Updated clinical data for OTX-2002 is expected in Q4 2024, with plans for expansion into monotherapy and combination settings.

• The company expects operating expenses to remain consistent with recent cost reductions and will continue to seek additional capital through equity, debt, or partnerships.